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Antibiotic resistanceFinding new, effective antibiotics is a challenging research area driven by novel approaches required to tackle un-
conventional targets. In this reviewwe focus on the bacterial protein secretion pathway as a target for eliminating
or disarming pathogens. We discuss the latest developments in targeting the Sec-pathway for novel antibiotics
focusing on two key components: SecA, the ATP-driven motor protein responsible for driving preproteins across
the cytoplasmicmembrane and the Type I signal peptidase that is responsible for the removal of the signal peptide
allowing the release of the mature protein from the membrane. We take a bird's-eye view of other potential tar-
gets in the Sec-pathway aswell as other Sec-dependent or Sec-independent protein secretion pathways as targets
for the development of novel antibiotics. This article is part of a Special Issue entitled: Protein trafﬁcking and se-
cretion in bacteria. Guest Editors: Anastassios Economou and Ross Dalbey.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
1.1. Antibacterial resistance and the dire need for new antibiotics
Due to their short life cycle and ability to adapt quickly to changes in
the environment, pathogenic bacteria continue to persist by gradually
overcoming the effect of drugs used to eradicate them. This natural
phenomenon of drug resistance is often hastened by human practices
due to inappropriate use of antibiotics. Currently, more than 70% of
pathogenic bacteria are resistant to most antibiotics available in the
market and the mortality rate due to bacterial infections is over 2 -
million per year, worldwide [1]. The older antibiotic classes discovered
more than 50 years ago — still in use after generations of synthetic
tailoring — target a limited set of cellular pathways (e.g. cell wall/
protein/folate biosynthetic pathways) or macromolecular structures
(DNA- and RNA-protein complexes, ribosomes and enzymes) [2].
Given that for any new antibiotic that enters the market, resistance
is observed within years or even months, new drugs with a novel
mode of action are needed to avoid cross-resistance (i.e. resistancesignal peptidase;Δ2–76 SPase I,
ane segment residues; SPase II,
se; FRET, ﬂuorescent resonance
s aureus
in trafﬁcking and secretion in
albey.
16337340.
,
ne@rega.kuleuven.be (J. Anné).to a particular antibiotic that often results in resistance to other antibi-
otics, usually from a similar chemical class, to which the bacteria may
not have been exposed). The past thirty years have seen only two truly
novel classes of antibiotics entering the market: the oxalidiones (linezo-
lid) and cyclic lipopeptides (daptomycin), for which resistant strains
have already emerged [3]. The problem of antibiotic resistance began es-
calating since the 1980swith a progressive increase in the number of in-
fections due to methicillin-resistant Staphylococcus aureus (MRSA),
vancomycin-resistant Enterococcus and ﬂuoroquinolone resistant Pseu-
domonas aeruginosa. Nevertheless, the number of pharmaceutical com-
panies working on antibiotic research and the number of newly
approved antibiotics dwindled sharply by 2010 [4]. The factors which
led to only about 4 to 5 pharmaceutical giants to continue their antibac-
terial research efforts are: antibiotic drug discovery is an expensive, slow
and uncertain process with an estimated cost of $800M per drug devel-
oped, time span of 8 to 15 years andwith a probability of approval of 1 in
a 100 drug candidates (from discovery and preclinical phase to new
drug approval) [5–7]. Antibacterial drugs are not lucrative as they are
only used in patients for a short period of time till the infection is cleared.
This contrasts with drugs for chronic diseases for which medication is
continued through the rest of the patient's lifetime. Lastly, as frequently
quoted for antibiotics “the low hanging fruits are already picked” and so
it is necessary to put inmore effort and adopt novel strategies forﬁnding
new antibiotics. Given the alarming increase in multidrug-resistant
pathogens, the dearth of new antibiotics and a dry drug-development
pipeline, the problem is gaining wide attention and seeks urgent action
[8–10]. A renewed interest in antibacterial research comes from bacteri-
al genome analysis, uncovering ~300 highly conserved essential pro-
teins that could serve as broad spectrum targets [11] in contrast to ~40
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ﬁnding newdrugs against new targets brings in newer challenges [5,12].
1.2. What is required of an ideal new target?
➢ Any novel antibiotic target should ideally be on the one hand essen-
tial, conserved and universal in bacteria and on the other lacking or
sufﬁciently dissimilar or non-essential in humans. Alternatively, tar-
gets that are not essential for growth but are required for virulence
or pathogenesis are also attractive as they do not impose a strong se-
lection pressure in bacteria thatmight lead to thedevelopment of re-
sistant strains. The idea behind anti-virulence targets is to attenuate
the pathogen and facilitate elimination by the host immune system.
➢ The target gene product should be stable in vitro and amenable for
high-throughput screens.
➢ Speciﬁc targets with known function, structure and properties are
desirable in initial drug-discovery efforts.
➢ The cellular location of the target is an important factor as it should
be relatively accessible for a potential new drug.
➢ It should be structurally and functionally distinct from a convention-
al target or site or pathway to avoid cross-resistance.
1.3. Why target the bacterial secretion pathway?
More than 30% of bacterial proteins are destined to function at the
cell envelope or outside the cell [13]. A vast majority of these proteins
with functionally diverse roles such as nutrient uptake, excretion, me-
tabolism, cell structure, communication, virulence and bacterial defense
are transported via the ubiquitous Secretion (Sec-) pathway. The Sec-
pathway is essential for viability, universally conserved in bacteria
(as well as in the endoplasmic reticulum (ER) of eukaryotes and thyla-
koid membranes in plants) and is the primary route for protein export.
These features and the fact that some Sec-pathway components are not
present in eukaryotes make it an attractive target.a)
Fig. 1a. A schematic representation of the Sec-pathway in E. coli. Preproteins synthesized at the
SecB. The Sec-translocase consists of SecYEG protein conducting channel, accessory proteins Se
cates the preprotein through the channel utilizing the energy from ATP hydrolysis. SPase I, a ser
mature protein. SPase II is an aspartic acid protease which cleaves lipoprotein substrates beneat
prepilins and pseudopilins at the cytoplasmic side of the membrane. YidC, a membrane prote
pathway (not shown). The locations of the N- and C-termini of the membrane enzymes are in
Figure adapted in part from [22].1.3.1. The Secretory (or the Sec-) pathway in bacteria
The three primary stages in protein secretion are: targeting to
the membrane, translocation across the membrane and the release of
the mature protein into the external environment (in Gram-positive
bacteria) or the periplasm (in Gram-negative bacteria) (Fig. 1a).
Gram-negative bacteria have additional branches (e.g. Type II and
Type V) for protein export across the outer membrane.
Proteins destined to function outside the cytoplasmic membrane
are generally synthesized as preproteinswith a small N-terminal exten-
sion called the signal peptide (SP). Signal peptides, usually found at the
amino terminus of secretory proteins, play a decisive role in targeting
and transport of preproteins. There are four kinds of signal peptides:
Sec- and Tat-type SPs, known as Type I signal peptides, lipoprotein or
Type II signal peptides, and Type IV or prepilin signal peptides [14].
Type I SPs have three recognizable regions namely a positively charged
amino-terminus (N-region), a central hydrophobic core (H-region) and
a neutral, but polar C-terminus (C-region), as shown in Fig. 1b. The
hydrophilic C-terminus contains the determinants for recognition
and processing by the signal peptidase. Type I SPs interact with
components of the Sec-machinery (SecA, SecY and the signal
peptidases) [15] and except for Tat SPs (which are less hydropho-
bic), are thought to delay preprotein folding so as to retain translo-
cation competence [16]. Type II SPs are similar to Type I SPs, but
cleavage occurs immediately upstream of a Cys residue, and these
are used to target lipoproteins. Type IV SPs differ from convention-
al N-terminal SPs in that they are usually very short and have no
classical tripartite structure [17,18].
Targeting of secretory proteins via the Sec-pathway occurs post-
translationally and in a poorly understood non-native state [19]. Some
of the newly synthesized preproteinswith export signals are recognized
and escorted by secretion-speciﬁc chaperones, SecB, CsaA or by general
chaperones, GroEL and/or DnaK [20]. In E. coli Sec B helps inmaintaining
20–30 preproteins in the unfolded, translocation-competent state and
targets the bound preprotein to the membrane for translocation.ribosomes are targeted to themembrane translocase, assisted by the cytosolic chaperone,
cDF (YajC, not shown) and the peripherally associated motor protein, SecA. SecA translo-
ine protease, cleaves non-lipoprotein substrates at the extracytoplasmic side, releasing the
h the extracytoplasmic membrane surface. SPase IV, also an aspartic acid protease, cleaves
in insertase, together with the SecYEG channel, inserts membrane proteins via the SRP-
dicated. The transmembrane helices are depicted as barrels.
P/G
A x A
-3   -1
N-region H-region  C-region Mature protein
P/G
-6 
SPase I cleavage siteb)
Fig. 1b. Tripartite structure of the Type I signal peptide. Bacterial Type I signal peptides typically contain a positively charged amino-terminal (N-) region, a central hydrophobic (H-) region
and a neutral but polar carboxy terminal (C-) region containing the SPase I recognition sequence (AXAmotif). Helix-breaking residues (Pro or Gly) are found in themiddle of theH-region
and at the boundary between the H- and the C-regions.
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volves (i) the SecYEG translocon which is comprised of three integral
membrane proteins SecY, SecE and SecG, together forming the
protein-conducting channel. (ii) The peripherally associatedmotor pro-
tein SecA, that drives the preprotein through the channel by repeated
cycles of ATP binding and hydrolysis. (iii) The accessory heterotrimeric
complex SecDFYajC, which closely associates with SecYEG and is pre-
dicted to function at the late stage of translocation possibly by pulling
the preprotein from the periplasmic side or promoting its folding [21].
During or shortly after translocation, if applicable, the signal peptide
is removed by the signal peptidase (SPase), allowing the release of the
mature protein from themembrane. Among the preproteins, themajor-
ity (non-lipoproteins) are processed by the Type I SPase (SPase I) while
lipoproteins are processed by the Type II SPase (SPase II). Precursors of
pilin and related pseudopilins (Section 4.2) are processed by the Type IV
SPase (SPase IV) [14,22]. Subsequently, the mature protein is folded at
the trans side of the membrane.
The Sec system (particularly the Sec YEG channel) along with a
membrane protein insertase YidC, is also involved inmembrane protein
insertion but the targeting of these proteins occurs by the signal recog-
nition particle (SRP) pathway (Section 4.3). In addition to the Sec path-
way, several bacteria utilize the Twin arginine translocation (Tat)
pathway for exporting a subset of proteins (Section 4.2), and although
there are differences in the targeting and the translocation apparati,
SPases I are common to both Sec and Tat pathways.1.3.2. Antibiotic targets in the Sec-pathway
The integral membrane proteins SecY and SecE are essential for via-
bility and protein translocation while SecG is not essential but increases
translocation efﬁciency [21]. The SecYEG proteins are universally con-
served, homologous to their eukaryotic counterparts Sec61 αγβ and
have no enzymatic activity, thus are not ideal targets. Interestingly, indi-
rect targeting of SecY by some antibiotics [23,24] suggests that there is a
potential to exploit such an approach. SecD and SecF are not essential
but improve the efﬁciency of translocation. The two proteins are not
present in eukaryotes but are not present in all prokaryotes either
[25,26]. Although not broad-spectrum, SecD and SecF may be exploited
as targets as their deletion results in severely reduced protein secretion
and growth and both proteins have large, soluble domains protruding
on the trans side of themembrane, andwould be accessible to potential
drugs [26]. YajC (a protein of unknown function) is neither essential for
cell viability nor for protein translocation [21,27].
SPase I and SecAwere the ﬁrst Sec-pathway components pursued as
targets. They are essential in bacteria and attractive as targets for which
HTS assays exist and a few inhibitors are already available. Type II signal
peptidases, Type IV signal peptidases and YidC are potential candidates
that have also been pursued in recent years.
In this review, we summarize the major developments, the current
situation and progress of SPase I (Section 2) and SecA (Section 3) as
antibiotic targets. We additionally brieﬂy discuss the efforts towards
targeting other components of the Sec-pathway as well as the other
pathways associated with bacterial protein secretion (Section 4).2. The Type I signal peptidase (SPase I) as an antibiotic target
2.1. SPase I: properties, structure, mode of action and its relevance as an an-
tibiotic target
Thephysiological role of theType I SPase (also known as “leader pep-
tidase”) is to release the mature protein from the membrane for it to
reach its correct cellular or extracellular destination [28]. Without
SPase I activity, the precursors remain membrane-bound due to the
uncleaved signal peptide acting as a membrane anchor [29]. Recent
studies indicate that the function of SPase I extends beyond secretion
and that they probably have a regulatory role as well. For example, the
SPase I from S. aureus cleaves and inactivates lipoteichoic acid synthase
(LtaS), a membrane embedded enzyme that synthesizes lipoteichoic
acid, an important cell envelope component of Gram-positive bacteria
[30].
SPase I (EC 3.4.21.89) is anunconventional serine proteasewhichdoes
not use the canonical Ser/His/Asp triad but instead utilizes a Ser/Lys
dyad and is classiﬁed into the evolutionary Clan SF, family S26 [31].2.1.1. Properties
Gram-negative bacteria (e.g., E. coli, Salmonella Typhimurium) typi-
cally have one chromosomally encoded SPase I which is essential and
constitutively expressed. One of the exceptions is P. aeruginosa, with
two Type I SPases (LepB and PA1303) each with a distinct role in phys-
iology and virulence [32]. Gram-positive bacteria (e.g., Bacillus subtilis
and Streptomyces lividans) often have more than one SPase I, of which
none of the individual enzymes is essential for cell viability on its own.
Exceptions include Streptococcus pneumoniae,Mycobacterium tuberculo-
sis and S. aureus [33]. SPases I are anchored to the membrane by one
(typically in Gram-positive) or more amino-terminal transmembrane
segments, (typically in Gram-negative bacteria). The carboxy-terminal
catalytic domain is signiﬁcantly smaller in SPases I of Gram-positive
bacteria compared to those of Gram-negative bacteria. Despite these
minor differences, SPases I contain ﬁve regions of high-sequence simi-
larity and identity referred to as boxes A to E, that are common and con-
served [29]. Box A consists of hydrophobic residues residing in the
membrane spanning regions of the SPases I. Box B and Box D contain
the catalytic Ser and Lys residues respectively, while Boxes C and E con-
tain residues important for substrate binding and for positioning of the
catalytic residues.
SPase I has substrate speciﬁcity for small and neutral residues at
−3 (or P3) and −1 (or P1) positions relative to the cleavage site
[34] (Fig. 1b). The SPase I recognition motif in the SP is referred to
as ‘Ala-X-Ala’, as a consequence of the frequent presence of Ala residues
at these positions. During preprotein translocation, the N-region of
the signal peptide acts as the topological determinant by following the
‘positive-inside rule’ of membrane proteins [35]. The H-region is be-
lieved to span the membrane as an α-helix, while the C-region adopts
a β-stranded conformation allowing access to the SPase I cleavage site
on the periplasmic side and processing [36]. The signal peptides
in Gram-negative bacteria are generally shorter than those in Gram-
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long enough to span the membrane, the H-region is believed to change
from an α-helix to an extended structure in the membrane [22]. Apart
from Sec substrates, SPase I processes preproteins with Tat signal pep-
tides (Section 4.3) and a few membrane proteins [22]. An interesting
example is the membrane-embedded enzyme LtaS (Section 2.1) with
ﬁve N-terminal transmembrane helices in which the Ala-X-Ala motif is
located not after an N-terminal signal peptide but 44 residues after the
last transmembrane domain [30]. For more details about the signal pep-
tide processing by SPases I, see Paetzel M [37].
The biochemical properties of E. coli LepB as well as SPases I from
Gram-positive bacteria B. subtilis, S. lividans, S. pneumoniae, (see review
[33]), and S. aureus [38] have been studied in detail. The common
in vitro properties of SPase I include: (i) concentration and time-
dependent, intermolecular-self cleavage leading to inactive fragments,
(ii) optimum activity requires non-ionic detergents (such as Triton-X-
100), (iii) phospholipids enhance activity and (iv) optimum pH varies
from pH 8 to pH 11, in contrast to classical serine proteases.
E. coli LepB is the best characterized among the SPases I [34]. A trun-
cated derivative, Δ2–76 SPase I (previously Δ2–75) lacking residues
2–76 corresponding to the transmembrane segment was designed, pu-
riﬁed and characterized in vitro [39,40] (Note that the E. coli numbering
was changed recently [41] owing to amissing residue in the sequencing
data. The results remain unaffected as the missing residue is from the
cytoplasmic loop region, only the numbering used in the previously re-
ported crystal structures are nowupby one number). TheΔ2–76 SPase I
is active in vitro, but less efﬁcient compared to the full-length SPase I
[42]. Crystal structures of the Δ2–76 SPase I in its Apo-form [40,43]
and in the complex with inhibitors [36,41,44,45] have helped in under-
standing the unique properties of the enzyme.
2.1.2. Structure and mode of action
Crystal structure of E. coli LepB Δ2–76 (Fig. 2) has a unique mostly
β-sheet protein fold, consisting of two antiparallel β-sheet domains,
domain I and II. Domain I contains all the conserved regions (boxes B–
E) in bacterial SPase I, while domain II (an insertion within domain I)Fig. 2. Structure showing SPase I bound to inhibitors. Structure of the catalytic domain o
E. coli SPase I in complex with (i) 5S-penem inhibitor and (ii) arylomycin A2/β-sultam in-
hibitors (superimposed). SPase I is shown as white molecular surface with the catalytic
dyad Ser/Lys highlighted in red. The 5S-penem inhibitor is shown in blue ball-and-stick
the arylomycinA2 inhibitor is shown inmagenta ball-and-stick, and theβ-sultam inhibitor
is shown as yellow ball-and-stick. A bound fragment of detergent, Triton X-100 is shown
in orange ball-and-stick. The approximate positions of the proposed substrate binding
sites and the membrane association surface are indicated.
Figure reproduced with permission from [45].f
,and an extendedβ-ribbon aremostly limited to Gram-negative bacteria
[36]. An unusually large hydrophobic surface that includes the catalytic
center and the adjacent substrate binding sites is the proposed mem-
brane association surface (Fig. 2). This surface, predicted to be in close
association with the membrane and capable of inserting into the lipid
bilayer during signal peptide cleavage, explains the detergent require-
ment of the SPase I for optimum activity and crystallization [36]. Two
shallow hydrophobic depressions appropriate for accommodating
small aliphatic residues form the substrate binding pockets S1 and S3
(Fig. 2) and provide the basis for Ala-X-Ala speciﬁcity. Site-directedmu-
tagenesis identiﬁed two Ile residues (Ile87 and Ile145, E. coli number-
ing) in the borderline between the S1 and S3 sites, contributing to the
high ﬁdelity and substrate speciﬁcity of the SPase I [46].
Paetzel et al. [14,34,37] proposed the proteolytic mechanism of the
bacterial SPase I which is illustrated based on current data. Brieﬂy, the
SP binds to the SPase I making β-sheet type hydrogen bonding interac-
tions with both β-strands that line the substrate binding sites of the
SPase I [44]. The P1 and P3 residues of the SP occupy the S1 and S3 bind-
ing pockets of the SPase I, respectively, while P5 and P7 residues occupy
potential binding sites S5 and S7, respectively [45]. P2 is solvent ex-
posed which explains the lack of speciﬁcity at this position. Upon sub-
strate binding, the -amino group of Lys146 (general base) abstracts a
proton from the side chain hydroxyl group of Ser91 (nucleophile), acti-
vating the Ser91Oγ for si-face attack on the carbonyl of the scissile bond
(SPase I cleavage site). The resulting tetrahedral intermediate I is stabi-
lized by an oxyanion hole formed by the Ser91main chain amide hydro-
gen and the Ser89 side-chain hydroxyl hydrogen group. The ammonium
group from the side chain of Lys donates a proton to the new amino-
terminus of the now mature protein and the tetrahedral intermediate
breaks down to produce signal peptide bound acyl-enzyme. Lys146
acts as a general base again by activating the deacylating water, which
forms the tetrahedral intermediate II. The Lys146 side-chain ammoni-
um group donates a proton to the Ser91 Oγ, resulting in the dissociation
of the signal peptide and regeneration of the SPase I active site.
2.1.3. Relevance as antibiotic target
SPases I are attractive targets because:
(i) they are ubiquitous and conserved in bacteria.
(ii) SPase I activity is essential for growth and viability in bacteria.
This was ﬁrst demonstrated by genetic [47] and functional stud-
ies [48] in E. coli. SPase I inhibition leads to accumulation of
preproteins in the cell membrane resulting in cell death [49].
(iii) SPases I differ sufﬁciently from their eukaryotic counterparts
(present in ER andmitochondria of humans) in structure, locali-
zation and catalytic mechanism, thereby reducing possibilities
for toxicity [14]. Unlike bacterial SPases I which are monomeric,
eukaryotic SPases aremultimeric complexes, located in the inner
membrane of mitochondria or in the lumen of the ER and in the
case of the latter, operate by the conventional Ser/His/Asp triad
mechanism or Ser/His dyad mechanism.
(iv) The Ser/Lys catalytic dyad mechanism and the si-face attack of
its substrates (rather than re-face attack used by most Ser-
dependent proteases), characteristic of the SPase I allows selec-
tive target inhibitionwithout inhibiting other essential proteases
in eukaryotes.
(v) The catalytic domain of the bacterial SPase I, exposed to the
outer leaﬂet of the plasma membrane, is accessible to poten-
tial inhibitors.
(vi) SPase I inhibition is likely to result in simultaneous attenua-
tion due to its role in virulence.
Molecular and functional analyses of the gene encoding SPase I
in several bacteria including human pathogens such as S. Typhimurium
[50], S. aureus [51], S. pneumoniae [52], Rickettsia rickettsii [53],
Legionella pneumophila [54], S. epidermidis [55], P. aeruginosa [32] and
M. tuberculosis [56] have conﬁrmed its essential role.
Table 1
SPase I (in vitro) activity with the two best substrates.
Substrates Speciﬁc enzymatic activity
(M−1 s−1)
Reference
Escherichia
coli LepB
Staphylococcus
aureus SpsB
Preprotein substrate
Pro-OmpA-nucleaseAa 1.1 × 107 16 [65]
Synthetic substrate
Decanoyl-LTPTAKA↓ASKIDD-OH 4.2 × 105 2.3 × 106 [67]
Amino acids are abbreviated as single letter codes. The arrow indicates the point of
cleavage and P1 and P3 residues are in bold.
a A hybrid protein made up of signal peptide of outer membrane protein A from E. coli
and the nuclease A from S. aureus.
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gent medical intervention:
S. aureus, responsible for a wide array of infections (including skin,
bone, lung and blood stream) and known for its remarkable ability
to develop resistance, has one active and essential SPase I, termed
SpsB. The enzyme is characterized in vitro and validated as a target
[38,51]. Several SpsB-dependent proteins required for virulence
such as extracellular proteases, lipases, superantigens, haemolysins
and leukocidins were identiﬁed by secretome proﬁling of S. aureus
[57]. SpsB also plays a role in the agr quorum sensing system,
which is important for bioﬁlm formation and virulence [58]. SpsB
is also suggested to have a regulatory role due to its proteolytic ac-
tion resulting in inactivation of LtaS, as discussed in Section 2.1.
P. aeruginosa, an opportunistic pathogen, naturally resistant tomany
frontline antibiotics, has two SPases I, LepB and PA1303, character-
ized recently. LepB is the essential and primary SPase I, while
PA1303 is non-essential with a likely function in the suppression of
virulence factor secretion through the quorum-sensing (QS) cascade
[32]. In silico analysis predicts 801 P. aeruginosa proteins (14.4% of
the genome) as containing putative SPase I substrates. The sub-
strates include components of the Sec-pathway, outer membrane
proteins and porins, ﬂagellar structural proteins, cell wall biosynthe-
sis enzymes as well as virulence factors including elastases (LasA
and LasB), endotoxin A, β-lactamase and proteins involved in bio-
synthesis of alginate, suggesting a direct role in house-keeping as
well as pathogenesis [32].
S. pneumoniae, responsible for considerable illness (including pneu-
monia, ear infections and meningitis) and mortality due to drug-
resistant strains, has one SPase I, Spi. It is also a well characterized
and validated target [52,59–61].
Listeria monocytogenes, a food-borne pathogen, has three paralogs of
SPase I, SipX, SipY and SipZ. Deletion of the sipZ gene (encoding the
major SPase I) results in impaired secretion of virulence factors (e.g.,
listeriolysin O and phospholipase C), rendering it almost avirulent
[62], highlighting the function of SPase I in virulence.
S. epidermidis, a common cause of nosocomial infections and
bioﬁlm-associated foreign body infections has two active SPases I
(Sip2 or SpsIB and Sip3) which are attractive targets not only in
free-living but also in bioﬁlm-associated S. epidermidis cells [55].
Consistent with its role in pathogenesis, secretome analysis of
SPase I-dependent proteins during stationary growth phase of
S. epidermidis, identiﬁed 11 proteins including peptidoglycan hydro-
lases, proteases and lipases, which are important for virulence [63].
M. tuberculosis has one essential Type I SPase, LepB [56]. LepB is a
promising target as demonstrated using an SPase I inhibitor (MD3,
a beta-aminoketone; see Supplementary Fig. S1 online)which is bac-
tericidal against actively growing cells and evenmore potent against
non-replicating or persistent cells [56]. However, the MD3 inhibitor
is not suitable for drug development due to compound instability.
2.2. SPase I inhibition assays
The entire range of SPase I assays used at different stages of inhibitor
search is summarized below.
2.2.1. In vitro inhibition assays
2.2.1.1. Preprotein processing assay. This assay involves incubation of the
puriﬁed SPase I and preprotein followed by separation of products by
SDS-PAGE [64]. Pro-OmpA-Nuclease A, a hybrid protein of S. aureus nu-
clease A fused to the signal peptide of E. coli outer membrane protein A
(OmpA) [34,65], is an excellent substrate for measuring in vitro activity
as well as for kinetic analysis of SPase I (Table 1). The assay is gel-based
and as such not ideal for HTS of inhibitors although it can be used as a
conﬁrmatory assay for SPase I inhibition [38].2.2.1.2. Fluorescent resonance energy transfer (FRET)-based assays. Syn-
thetic substrates for SPase I are short stretches of residues, identical
to those in the signal peptide region of preproteins containing the
SPase I recognition and cleavage site. Peptides that are at least 9-mers
and in addition have SP-like features incorporated in them are far better
substrates. For example, Stein et al. [66] appended K5-L10 to incorporate
a positively charged N-terminus and a hydrophobic core, respectively
(see Table 2, substrate 1) whereas Bruton et al. [67] incorporated a
decanoyl moiety (mimicking a membrane anchor) and a turn inducing
motif (proline at P5 position) as shown in Table 1 (substrate 2) and
Table 2 (substrate 4).
A difference in substrate speciﬁcity of SPases I is observed even with
the synthetic substrates (see review [68]). Thus in vitro inhibition
assays developed for SPases I from Gram-negative E. coli and Gram-
positive pathogens, S. pneumoniae, S. aureus and S. epidermidis, involve
speciﬁcally designed substrates (see Table 2). The in vitro assays facili-
tated the characterization and comparison of SPases I from different
bacteria. Often these assays are FRET-based, allowing rapid measure-
ment and some are already optimized for high-throughput screening
of inhibitors. The in vitro inhibition assay for S. pneumoniae was used
for high-throughput screening of 50,000 pre-fractionated natural
product samples [59], of which only one sample inhibited SPase I. This
was identiﬁed as lipoglycopeptide or Arylomycin C (Section 2.3.3). We
optimized a high-throughput FRET-based assay for S. aureus SpsB and
screened ~26,000 diverse small molecules (average Z′ value [69] of 0.
73) but did not obtain potent hits [38,70]. Z′ scores are measures of
standard deviation, derived using the formula:
Z Prime or Z′ ¼ 1− 3σcþ þ 3σc−
 
μcþ−μc−
 
where, σC+ and σC− are standard deviations of positive and negative
controls, respectively while μC+ and μC− are the means of positive and
negative controls, respectively.
The in vitro efﬁcacy of a rationally designed peptide aldehyde inhib-
itor (Section 2.3.2) was demonstrated using the SpsB FRET assay [71].
2.2.2. In vivo assays
The secretion of β-lactamase, a Sec-dependent substrate, is used to
gauge in vivo SPase I activity/inhibition. Initially, whole cell pulse-
chase analysis of processing of pre-β-lactamase to β-lactamase in
E. coli was used to demonstrate the inhibition of preprotein processing
in situ by a SPase I inhibitor, penem [72]. This test is now replaced by
the β-lactamase secretion assay.
2.2.2.1. β-lactamase secretion assay in S. aureus. The assay involves mea-
surement of hydrolysis of nitroceﬁn, a chromogenic β-lactamase sub-
strate in culture supernatants incubated in the presence and absence
of an inhibitor. The assay is used as a secondary assay for SPase I inhibi-
tion [59,73].
Table 2
SPase I substrates for rapid screening of inhibitors in FRET assays.
Sl. no. Synthetic peptide substrate
sequence a
Preprotein used for peptide design Microorganism/SPase I (kcat/KM) Reference
1. K(5)-L(10)-Y(NO2)FSASALA↓KIK(Abz) Maltose binding protein from Escherichia coli E. coli LepB
(2.5 × 106 M−1 s−1)
[66]
2. KLTFGTVK(Abz)PVQA↓IAGY(NO2)EWL Streptokinase from Streptococcus pyogenes S. pneumoniae Spi
(2.7 × 102 M−1 s−1)
[61]
3. (Dabcyl)-ADHDAHA↓SET-(EDANS) SceD from Staphylococcus aureus S. aureus SpsB
(1.85 × 103 M−1 s−1)
[38]
4. Decanoyl-k(Dabcyl)-TPTAKA↓ASKKD-D(EDANS)-NH2 Consensus preprotein cleavage sites in
S. aureus
S. aureus SpsB [73]
5. (Dabcyl)VSPAAFA↓ADL(EDANS) LasB elastase from Pseudomonas aeruginosa P. aeruginosa LepB and PA1303 [32]
a Amino acids are abbreviated as single letter codes. The arrow indicates the point of cleavage and P1 and P3 residues are in bold.
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These have an advantage over the assays mentioned above as com-
pounds are tested based on both the mode of action as well as the anti-
bacterial activity. These assays are based on the observation that
reduced expression of an essential target gene renders the strain sensi-
tive to compounds that inhibit that particular gene product or pathway.
2.2.3.1. Regulated expression of SPase I. A cellular assay employing an
E. coli strain underexpressing lepB gene was validated for testing SPase
I inhibitors using penem, a known SPase I inhibitor [74]. The strain has
E. coli lepB under an arabinose regulatable promoter cloned onto a plas-
midwhile the chromosomal lepB genehas been removed. The assaywas
used as a secondary assay to test three potential inhibitors derived from
HTS in vitro. The inhibitors did not have signiﬁcant antibacterial activity
against E. coli [74]. Recently, one of the inhibitors, MD3, was reported to
be active againstM. tuberculosis (MIC99 of 17.7 μM) [56] (Section 2.1.3).
InM. tuberculosis, a lepB overexpression strain showed reduced sus-
ceptibility to the aforementioned β-aminoketone inhibitor while the
lepB underexpression strain showed increased susceptibility to the in-
hibitor, validating SPase I as the target [56].
2.2.3.2. Bacterial target array -S. aureus ﬁtness test (SaFT) proﬁling. This is
a method to determine the mode of action of a new compound by si-
multaneous screening against all essential bacterial gene targets. It is
based on 245 S. aureus antisense RNA strains, each of which is
engineered for reduced expression of (conserved, broad-spectrum) tar-
get genes essential for its growth [75]. Brieﬂy, this semi-automated
method involves growth of strains in the presence and absence of test
compounds, determination of relative abundance of the strains by mul-
tiplex PCR, capillary electrophoresis and DNA fragment analysis to
quantify strain-speciﬁc markers [75,76]. This strategy adopted by
Merck resulted in ﬁnding several new classes of natural compounds
[11] including inhibitors for the Type I signal peptidases [73].
2.3. Overview of SPase I inhibitors
SPases I are insensitive to classical protease inhibitors including ser-
ine protease inhibitors [34]. Based on the observation that there is at
least one other enzyme (signal peptide peptidase A) operating with
the same Ser-Lys catalytic dyadmechanism that is inhibited by common
serine protease inhibitors, Dalbey et al. [22] suggested that serine prote-
ase inhibitors do not bind with high afﬁnity to SPase I.
The search for effective inhibitors for SPase I, a challenging task from
the start [77] has led to some exciting developments as illustrated
below.
2.3.1. Discovery of Penems (β-lactam type inhibitors)
Although the essential role of SPase I in E. coli was demonstrated in
the early eighties [47,48], themechanism of action of SPases I remained
unclear till the late nineties. Two pharmaceutical companies discoveredβ-lactam inhibitors of SPase I: monocyclic azetidinones, the ﬁrst (non-
peptide) inhibitors effective against E. coli LepB albeit at very high con-
centrations (500 μM) [78]; and 5 S-Penem stereoisomers, the ﬁrst po-
tent irreversible inhibitors [79] (Table 3, inhibitor 1). Extensive
in vitro screening and optimization efforts at GlaxoSmithKline
(previously SmithKline Beecham) [72,77,80,81] resulted in a few potent
inhibitors including allyl (5S, 6S)-6-[(R)-acetoxyethyl]-penem-3-
carboxylate (Fig. 3), with an IC50 of 0.38 μM against E. coli LepB. Based
on the 5S-stereochemistry of the inhibitor, it was proposed that SPase
I attacks the peptide backbone of its substrates from the si-face (uncom-
mon for serine-dependent hydrolases) rather than from the re-face.
The inhibitor was co-crystallized with the catalytic domain of the
SPase I to obtain a high resolution structure that provided a direct
proof of SPase I utilizing the Ser/Lys catalytic dyad mechanism [36].
The structure showed that Ser 91 (E. coli numbering) attacks the si-
face of the β-lactam amide bond which is a peptide bond analog. The
crystal structure by Paetzel et al. [34,36] provides valuable information
on the active site, helps explain the unique characteristics of the enzyme
and serves as a template for inhibitor design. Despite high in vitro activ-
ity, the penem-type inhibitors (Fig. 3), generally have poor antibacte-
rial activity (Table 3, inhibitors 1 and 2) likely due to low cell wall
penetration or compound instability [77,82], limiting their clinical
application. A couple of exceptions noted in a recent study are that
penem and a carbamate-derivatized penem are moderately effective
against S. epidermidis and MRSA, respectively [83] (Table 3, inhibitors
3 and 4).
2.3.2. Designing peptide, lipopeptide and peptide aldehyde inhibitors
Early studies proved that (i) SPases I are competitively inhibited by
signal peptides in vitro [84]. (ii) Preproteins or synthetic substrates
with Pro at+1 position inhibit SPase I activity in vivo, leading to an im-
paired growth of cells [85,86]. Attempts at designing peptide inhibitors
based on the classical approach used for serine protease inhibitors did
not work initially for the SPase I [77] till researchers at GlaxoSmithKline
ﬁnally came up with highly effective lipopeptide inhibitors [67] and a
substrate for in vitro inhibition assay (Table 1, substrate 2). The peptides
were based on the consensus sequence of preproteins in S. aureus and
designed to incorporate key structural elements of a signal peptide,
namely an alkyl membrane anchor, a helix breaking Pro at P5 and a
Lys at P2 (for the AKA). Insertion of Pro at +1 converted the peptide
into a competitive inhibitor while incorporation of α-ketoamide at the
cleavage site transformed it to a time-dependent inhibitor of S. aureus
SpsB (IC50 of 0.6 and 0.1 μM, respectively) [67] (Table 3, inhibitors 5
and 6). The antimicrobial activity of the lipopeptide is undisclosed. Fur-
ther optimization resulted in a lipopeptide aldehyde inhibitor (Fig. 3)
with increased potency against SpsB (IC50 of 0.09 μM) butwith poor an-
timicrobial activity [71] (Table 3, inhibitor 7). These studies proved the
critical role of N-terminal fatty acid for potency of the inhibitor in vitro
as well as in vivo. It is presumed that it probably mimics the hydropho-
bic region of the signal peptides in preproteins. This also explains why
peptides as such did not prove to be effective inhibitors. Interestingly,
Table 3
SPase I inhibitors with their in vitro and in vivo activities.
Sl. no. Inhibitor SPase IC50a(μM) Microorganism MIC (µM) Reference
Penems
1. Allyl (5S,6S)-6-[(R)-acetoxyethyl] penem-3-carboxylate LepB 0.38 Escherichia coli – [77]
2. (5S)-Tricyclic penem LepB 0.2 E. coli – [82]
SpsB 5 MRSA N272
3. (5S,6S)-6-[(R)-hydroxyethyl] penem core with a
C3 p-nitrobenzyl protected carboxylic acid
E. colib ≥596 [83]
Staphylococcus aureus ≥596
Staphylococcus epidermidis 149
4. Carbamate-derivatized penems (ethyl) MRSA 247 [83]
(isopropyl) 238
Rationally designed peptides/lipopeptides
5. Decanoyl-LTPTAKAPSKIDD-OH SpsB 0.6 S. aureus – [67]
6. Decanoyl-LTPTANA-α-ketoamide analogs SpsB 0.1–16 S. aureus – [67]
7. Decanoyl-PTANA-aldehyde SpsB 0.09 S. aureus 205 [71]
LepB 13.4 E. coli N819
8. (D)-KLKL6KLK-NH2 LepB 30 E. coli 16 [87]
E. colib 4.8
S. aureus 8
Streptococcus pneumoniae 4.8
Haemophilus inﬂuenzae N64
Arylomycins
9. Arylomycin A2 LepB – E. coli (P)c N128 [91–93]
S. aureus(P)c N128
Pseudomonas aeruginosa (P)c N128
S. epidermidis (S)c 1
10. Arylomycin A-C16d (synthetic arylomycin A2
derivative with a longer fatty acid tail)
S. hominis (S)c 0.25
Corynebacterium glutamicum (M)c 2
Rhodococcus opacus (V)c 2
Helicobacter pylori (A)c 4
S. pneumoniae (N)c 16
S. pyogenes (A)c 16
11. Arylomycin C (Lipoglycopeptides) LepB 0.11–0.19
2.4–24.9
E. coli 4–8 [59]
S. pneumoniae 8–64
Spi S. aureus 32–64
H. inﬂuenzae ≥64
12. Actinocarbasin (Arylomyicn D) SpsB 0.05 MRSA
MRSA strain COL
5.9 0.3+ IPMe [73]
13. M131 (synthetic derivative of Actinocarbasin) SpsB 0.01 MRSA
MRSA strain COL
1.2 0.15 + IPMe [73]
Krisynomycin
14. Krisynomycin SpsB 0.12 MRSA
MRSA strain COL
46.2 2.9 + IPMe [73]
MIC: Minimum inhibitory concentration.
a Half-maximal (50%) inhibitory concentration.
b Polymyxin B nonapeptide permeabilized cells.
c Resistance-conferring Pro or other residues at analogous position (see text), denoted as amino acid single letter code.
d Arylomycin A-C16 was formerly called arylomycin C16.
e Imipenem (IPM) susceptibility (MIC = 13.4 μM) restored by SPase I inhibitors.
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microbial peptide from Sacrophaga peregrina (ﬂesh fruit ﬂy) inhibits
E. coli LepB (IC50 of 30 μM) and has antibacterial activity against E. coli
(MIC = 16 μM), S. aureus (8 μM) and S. pneumoniae (4.8 μM) [87]
(Table 3, inhibitor 8).
2.3.3. Discovery of natural product Arylomycins
Arylomycins are among the most extensively studied SPase I inhibi-
tors as they are the ﬁrst inhibitors with signiﬁcant antibacterial activity.
There are currently four related families of arylomycins (including
actinocarbasin, Section 2.3.4) identiﬁed by independent groups.
Arylomycins (A and B series) were ﬁrst reported in 2002 with
their structure and limited antibacterial activity [88,89]. Subsequently,
the crystal structure of Δ2–76 SPase I in complex with a member,
Arylomycin A2, revealed their mechanism of action [44]. Lipogly-
copeptides (Arylomycin C series) were identiﬁed in parallel (by Eli
Lilly and Company) as inhibitors of E. coli and S. pneumoniae SPases I
in a high-throughput FRET-based assay (Section 2.2.1.2) [59]. Modest
antibacterial activity was observed against a few pathogens [59]
(Table 3, inhibitor 11).Arylomycins are secondary metabolites from Streptomyces spp.,
synthesized by nonribosomal peptide synthesis. They are lipohexa-
peptides with a common core structure consisting of a [3,3] biaryl-
linked tripeptide macrocycle at the C-terminus and a fatty acid tail
attached to the N-terminus (Fig. 3). Arylomycin B series differ from A
by nitro-substitution of the tyrosine residue (Fig. 3). Arylomycin C series
differ from the A series by glycosylation, and in some cases hydroxyl-
ation of the macrocycle and a longer fatty acid tail [59,90] (Fig. 3).
ArylomycinA2 does not inhibit the growth of E. coli, P. aeruginosa and
S. aureus, while it is highly potent against S. epidermidis (MIC of 1 μg/ml)
[91] (Table 3, inhibitor 9). In an interesting study, Romesberg et al. [92]
demonstrated that S. epidermidis develops resistance to arylomycin by a
point mutation (Ser to Pro at residue 29) in SpsIB, one of the two active
SPases I. The resistance-conferring Pro is responsible for natural resis-
tance to arylomycins in bacteria such as E. coli, P. aeruginosa and in
some strains of S. aureus. The absence of Pro is often predictive of
arylomycin sensitivity with only a few exceptions [92] (Table 3, inhibi-
tor 10). The otherwise broad-spectrum activity of arylomycins was
demonstrated using a synthetic derivative with a longer fatty acid tail
(Arylomycin A-C16) [92]. In fact its potency against a few coagulase-
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hominis, Staphylococcus lugdunensis) is equal to or greater than that of
vancomycin, commonly prescribed for treatment of MRSA [93].
Themolecular basis for resistance was provided by the crystal struc-
ture of arylomycin in complex with the E. coli SPase I [44] which shows
that the resistance-conferring Pro residue is present in a less conserved
region of the SPase I (away from the catalytic center but within
the substrate binding pocket) with which arylomycin interacts [92].
The mutation reduces the binding afﬁnity of arylomycin with the
SPase I. Chemical synthesis of arylomycins (A, B and C series) and
their derivatives have facilitated structure–activity relationship (SAR)
studies (see review [90]). Synthetic arylomycin derivatives (withmeth-
ylene units in the arylomycin backbone) designed to compensate for the
unfavorable interactions caused by the resistance-conferring Pro, re-
stored some activity against wild-type S. aureus [90]. Thus, arylomycinsFig. 3. Chemical structures of SPaseare natural antibiotics for which resistance has evolved and so their
broad-spectrum activity ismore likely to be restored by synthetic tailor-
ing compared to molecules that have never been antibiotics [90]. The
crystal structure data provides additional possibilities for optimizing
the arylomycin scaffold.
Arylomycin A2 binds non-covalently to the SPase I in a manner
thought to mimic its natural substrates. The inhibitor position in the
binding pocket with its C-terminal tripeptide macrocycle points
towards the active site and makes a parallel β-strand interaction with β-
strand that lines the SPase I binding cleft. The methylene groups of the
C12 fatty acid make Van der Waals interaction with the predicted mem-
brane association surface of the SPase I. This provides a rationale for the
critical role of amino-terminal fatty acid for effectiveness of SPase I
inhibitors and substrates. SAR studies in arylomycin indicate that a mini-
mum of C12 tail is required and those up to C16 are ideal [90]. The crystalI inhibitors indicated in Table 3.
Fig. 3 (continued).
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hibitor,morpholino-β-sultamderivative (BAL0019193; see Supplementa-
ry Fig. S1 online) also suggests a scope for further optimization. The β-
sultam derivative binds noncovalently at the active site, taking a parallel
orientation relative to the biaryl ring moiety of arylomycin, deﬁning a
novel space that can be occupied by optimizing the arylomycin scaffold
[45] (Fig. 2). The structure of SPase I in complex with a lipoglycopeptide
(arylomycin C) derivative shows that the sugar moiety is directed away
from the binding site, suggesting that other modiﬁcations may be made
at this position to possibly optimize the pharmacokinetics of the scaffold
[41]. A recent study showed that C-terminal homologation with a glycyl
aldehyde and the addition of a positive charge to the macrocycle increase
the activity and spectrum of arylomycin [94].A study used model strains of E. coli and S. aureus (with a point mu-
tation to remove the resistance-conferring Pro) to demonstrate that the
antibiotic activity of arylomycins is a result of insufﬁcient SPase I activity
and it can be either bacteriostatic or bactericidal, depending on the
organism and growth conditions [95]. In addition, arylomycins show
relatively little synergy or antagonismwithmost other antibiotic classes
with the exception of gentamicin, an aminoglycoside, with which it
shows synergy (Table 4).
2.3.4. Discovery of actinocarbasin and krisynomycin
Actinocarbasin and krisynomycin are structurally distinct, natural
products with signiﬁcant antimicrobial activity, identiﬁed by a reverse
genomic approach [73]. This approach (also sometimes referred to as
Fig. 3 (continued).
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genetics), is to screen for compounds with antibacterial whole cell ac-
tivity and then determine their mechanism of action using various bio-
chemical and genetic approaches. Imipenem (a carbapenem) is a highly
successful β-lactam antibiotic which is ineffective against MRSA. To
ﬁnd potentiators of imipenem (a second agent added to ﬁght speciﬁc
resistance to imipenem) against MRSA, a high-throughput, MRSA agar
growth assay was used to screen molecules derived from microbial ex-
tracts [73]. This led to identifying krisynomycin (a cyclic depsipeptide)
isolated from Streptomyces fradiae strain MA7310 and actinocarbasin
(a lipoglycopeptide) from Actinoplanes ferrugineus strain MA7383. The
two molecules potentiate the activity of imipenem at a concentration
16-fold below their native MIC value (Table 3, inhibitors 12 and 14).
An optimized synthetic derivative of actinocarbasin, M131 (Fig. 3)
has improved potency and synergy with imipenem (Table 3, inhibitor
13). The cellular target of actinocarbasin, M131 and krisynomycin
was identiﬁed as the SPase I, SpsB, by S. aureus ﬁtness test proﬁling
(Section 2.2.3.2). Their potency was conﬁrmed in a FRET-based assay
(Section 2.2.1.2) and β-lactamase secretion assay (Section 2.2.2.1).
Actinocarbasin has the same coremacrocycle as the arylomycins but
with O-sulfonation on the aryl rings and extensive modiﬁcation of the
lipopeptide tail (Fig. 3), and hence recently grouped into the arylomycin
D series [90]. Krisynomycin (Fig. 3) belongs to a new structural class.
Synergy of the molecules with imipenem against MRSA clinical
isolates was demonstrated using the checkerboard method [73](Table 4). Thieren et al. [73] demonstrated that the synergy of the
SPase I inhibitors is speciﬁc to the β-lactam class (including penicillins,
cephalosporins and carbapenems, except for ceftazimide) and not for
any other classes of antibiotics tested and speciﬁc for MRSA. Synergy
of M131 with imipenem is also effective in vivo, in murine models of
MRSA infection; and importantly, combining imipenemwith SPase I in-
hibitor M131 suppresses the emergence of M131 resistance.
β-lactams are the most successful antibiotics for treatment of bacte-
rial infections caused by numerous species, spanning 60 years and
representing over 65% of the world antibiotic market [96]. Given that,
combination therapy is expected to account for the most common use
of the β-lactams in future [96], the synergy of β-lactam antibiotics with
SPase I inhibitors holds the potential to broaden the spectrum of
β-lactams againstMRSA and also reduce the emergence of resistant strains.
2.3.5. Potential SPase I inhibitors from in silico screens
InM. tuberculosis, although targeting LepB might potentially lead to
eliminating persistent bacteria and shorten therapy, neither compound
MD3 (used for target validation [56]) nor arylomycin (due to the pres-
ence of resistance conferring Pro in its SPase I) can be currently pursued.
Recently, a high-throughput virtual screening of 169,109 natural
compounds (from the ZINC database; http://zinc.docking.org) using a
model of the 3D structure of theM. tuberculosis SPase I, resulted in the
identiﬁcation of twodifferent inhibitors EMP and PHM(see Supplemen-
tary Fig. S1 online), which bind to the active site of the enzyme in silico
Table 4
Synergy of SPase I inhibitors with Imipenem (β-lactam) and Gentamicin (an aminoglycoside) determined by checkerboard analysis.
Antibiotic + SPase I inhibitor FIC index rangea Microorganism Reference
Imipenem + Actinocarbasin 0.19–0.42 Clinical isolates of MRSA [73]
Imipenem + Krisynomycin 0.15–0.26 Clinical isolates of MRSA [73]
Gentamicin + Arylomycin A-C16b 0.55 ± 0.11–0.91 ± 0.25c Escherichia coli PAS0260d [95]
Gentamicin + Arylomycin A-C16b 0.46 ± 0.12–0.83 ± 0.22c Staphylococcus aureus PAS8001d [95]
a FIC: Fractional inhibitory concentration; FIC of a test agent in a particular combination is theMIC of that agent in the combination divided by theMIC of that agent when tested alone.
FIC index is the sum of the FICs of the two antibiotics. FIC indexes of ≤0.5 reﬂect signiﬁcant synergism, while FIC indexes ≥2 reﬂect signiﬁcant antagonism.
b A synthetic derivative of arylomycin A2, with a longer fatty acid tail.
c Averages of minimum and maximum FIC values observed, respectively ± standard deviations.
d Mutant strains which differ from the WT, by a point mutation that converts resistance conferring Pro to Leu or Ser, for increased arylomycin sensitivity.
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in the active site and substrate binding pockets. PHM forms a hydrogen
bond with the nucleophilic Ser. The compounds are yet to be validated
in vitro and for their antibacterial activity againstM. tuberculosis.PBD
WD 
SD
IRA2
NBD
C-terminal domain
ADP
Fig. 4. Crystal structure of B. subtilis SecA. Ribbon diagram of B. subtilis SecA showing the
structural domains: NBD in yellow, IRA2 in blue, the PBD in orange, the SD in green, and
the WD in cyan. ADP is shown in a ball-and-stick representation.
Figure reproduced from [101]with Copyright (2004) National Academy of Sciences, U.S.A.3. SecA as an antibiotic target
3.1. SecA: properties, structure and mode of action; relevance as an antibi-
otic target and druggable sites
3.1.1. Properties, structure and mode of action
SecA is a mechanoenzyme with an N-terminal ATPase domain and
a C-terminal speciﬁcity domain (MW 102 kDa, in E. coli). The crystal
structures of SecA from E. coli [98,99], M. tuberculosis [100], B. subtilis
[101–105], T.maritima [103,104], T. thermophilus [106], show a common
structural and functional domain organization (Fig. 4).
SecA is classiﬁed into the superfamily II (SF2) DEAD (DExH/D) pro-
teins, which includes nucleic acid helicases [107,108]. Functionally,
helicases utilize energy fromATP hydrolysis to bind and unwind nucleic
acid substrates, while SecA uses this chemical energy to bind andmobi-
lize polypeptide substrates through the protein conducting channel.
Structurally, both SecA and helicases contain two RecA-like subdomains
withWalker A and Bmotifs [109], that form the helicase or DEADmotor
[108]. DEAD is the acronym for the conserved sequence—Asp-Glu-Ala-
Asp—in this family of proteins. The glutamate is the catalytic base that
activates water for hydrolytic attack on ATP [110] and the aspartate li-
gates the Mg2+ cofactor of ATP [109,111]. In SecA the two subdomains
are called nucleotide-binding domain (NBD) (Chatzi et al., in press, this
volume) (Fig. 4) and IRA2 (intramolecular regulator of ATPase2). The
ATPase active site in SecA is located at the interface of the two
subdomains [112]. Recent biophysical data [111] show that a single
electrostatic charge in the ATPase active site controls the global confor-
mation of SecA.
SecA also has two speciﬁcity domains, which distinguishes it from
other SF2 proteins: the C-domain that is linked to IRA2 and the
preprotein binding domain (PBD) which is rooted inside NBD. The
C-domain contains 4 substructures: the long α-helical scaffold do-
main (SD); the conserved helix-loop-helix IRA1 switch (also
known as two-helix ﬁnger); the α-helical wing domain (WD); and
the C-terminal tail (C-tail) that binds Zn2+ [105,108]. The SD con-
tacts all other domains of SecA, controls the opening and closing of
the DEAD motor, and is involved in preprotein binding along with
the PBD [113]; IRA1 negatively regulates cytosolic SecA ATPase ac-
tivity (in the resting state) [114], makes important interactions
with the SecYEG channel (during translocation) [115] and contains
residues involved in SecA dimerization [116,117]; WD and the C-
tail are involved in SecB and lipid binding [113].
The PBD contains an anti-parallel β-strand (stem) and a bilobate
globular domain (bulb). The crystal structures show that the PBD bulb
undergoes an approximately 75° swiveling motion between a ‘closed’
and an ‘open’ state (which could accommodate preproteins or regions
of SecYEG) [108]. The movement of PBD creates two grooves on the
surface of SecA: the large groove 1, formed between PBD, WD and SDis involved in signal peptide binding [116,118,119] and the expandable
groove 2 (known as “the clamp”), created at the interface of PBD and
IRA2, was proposed to bind mature regions of the preprotein [104].
Large-scale conformational changes of the PBD are expected to be re-
quired for initiation of the translocation process [120].
SecA is a ﬂexible enzyme, a property that aids its interaction with
multiple ligands and also its motor function [104,112,121]. SecA inter-
acts with nucleotides, preproteins, signal peptides [118], SecB [122]
and other chaperones, ribosomes [123] as well as other components
(see below), all of which inﬂuence its activity [112]. Brieﬂy, anionic
phospholipids (phosphatidylglycerol and cardiolipin) are important
for SecA binding to the membrane while nonlamellar-prone lipids
(diacylglycerol and phosphatidylethanolamine) speciﬁcally enhance
SecA binding to the bilayer. SecA binds to themembranewith low afﬁn-
ity at acidic phospholipids and with high afﬁnity (low nM) at the
SecYEG channel [112]. Binding of SecA to the various ligands and ﬁnally
to the SecYEG-SecDFYajC complex allosterically stimulates the ATPase
activity of SecA for driving the translocation process.
SecA-mediated targeting and secretory protein translocation across
the E. coli inner membrane is detailed in Chatzi et al., in press (this vol-
ume). The mode of action of SecA, based on existing biophysical and
biochemical data [108,113], is brieﬂy outlined here: cytosolic SecA
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1), binds with high afﬁnity to SecYEG leading to a conformational
change. This results in a moderate increase in ATPase activity—termed
the membrane ATPase—and an increased afﬁnity for preproteins and
SecB (priming, stage 2). SecB targets the unfolded preprotein to SecA
bound to SecYEG. Preprotein binding to SecA results in a substantial
increase in ATPase activity—termed the translocation ATPase—due to
the opening of a highly conserved salt bridge (gate 1) at the base of
the DEAD motor which renders it in a loose state with decreased
afﬁnity for ADP (triggering, stage 3). The release of ADP changes the
conformation of SecA PBD together with bound preprotein. SecB is re-
leased (pre-insertion, stage 4). ATP binding to the DEAD motor drives
additional conformational changes that enables deeper insertion of
SecA into the membrane. The bound signal peptide penetrates the
membrane, 20–30 amino acid segment of the mature part is threaded
into the SecYEG channel (ATP stroke, stage 5). ATP hydrolysis causes a
partial release of preprotein into the channel and conformational
changes in SecA. This allows SecA to revert back to its compact, ADP-
bound state and to de-insert from the membrane, a step accelerated
by the proton motive force (de-insertion, stage 6). The next round of
ATP binding and hydrolysis proceeds as SecA PBD moves further
down the preprotein, triggering ADP release. The steps 3 to 6 are repeat-
ed till the protein is translocated across themembrane (multiple rounds
of catalysis, step 7).
Recently, SecA has also been proposed to function alone as an ion
and protein-conducting channel [124,125].
3.1.2. Relevance as antibiotic target
The factors that make SecA an attractive target are:
(i) SecA is ubiquitous and conserved in bacteria [25].
(ii) It is essential for bacterial cell viability as demonstrated by con-
structing temperature-sensitive mutants of E. coli and B. subtilis
[126–128] andbygene knockout technique in E. coli [129]. Growth
of temperature-sensitive secAmutants at non-permissive temper-
atures (42 °C) leads to defective protein secretion and cell division
and ﬁnally to cell death [127,128].
(iii) SecA or a homolog is absent from humans as conﬁrmed by sub-
tractive genomics approach [130].
(iv) SecA is a cytoplasmic target and a peripheral membrane protein.
Although any potential inhibitor needs to cross the membrane
barrier(s), SecA should still be accessible to many compounds.
During some stages of the catalytic cycle SecA is expected to
have parts buried in the membrane [131–133]. The recent view
of SecA functioning as an ion and protein conducting channel
[124] also means that SecAmight be more accessible for potential
inhibitors.
(v) SecA has several interactions and enzymatic activities, providing
greater options for targeting.
(vi) Targeting SecAwill drastically reduce bacterial virulence since the
newly synthesized virulence proteins that depend on SecA-
mediated protein transport will be locked up in an unfolded
state within the bacterial membrane.
Mycobacteria and some Gram-positive bacteria (including Listeria,
Staphylococcus and some Streptococcus species) possess two homo-
logues of SecA called SecA1 and SecA2 (see review [134]). In bacteria
with two SecAs, the two enzymes have non-overlapping functions:
SecA1 is the essential ‘house-keeping’ ATPase in the Sec-pathway
(similar to SecA of E. coli and B. subtilis) while SecA2 is a nonessential
ATPase, responsible for exporting a subset of proteins which are linked
to virulence in many pathogens. Exceptions are C. glutamicum (non-
pathogenic soil bacterium) and C. difﬁcile (themajor cause of nosocomi-
al antibiotic-associated diarrhea), in which SecA2 is also essential [134].
The conservation of the functional domains across SecA (and SecA1)
and SecA2, offers the possibility of developing inhibitors targeting
both SecA proteins to inhibit growth as well as virulence [24].We conﬁne our discussion to SecA (or SecA1) whose essentiality is
conﬁrmed in several bacteria including pathogens such as H. inﬂuenzae
[135], mycobacteria [136], S. aureus [137] and Burkholderia
pseudomallaei [138]. SecA is a broad-spectrum, druggable target
[130] for which structural, biochemical and biophysical information,
high-throughput screening assays and inhibitors are progressively
evolving.
3.1.3. Druggable sites
SecA ATPase activity is essential for translocation [26] while SecA
helicase activity is not essential for translocation in vivo. An obvious
strategy is to ﬁnd inhibitors of SecA ATPase activity. However, the nucle-
otide binding (DEAD motor) domain of SecA is conserved in other
ATPases as well (e.g., ATP-dependent helicases, F1 ATPase, AAA ATPases
and ABC transporters [111]). Consequently catalytic inhibitors of SecA
are likely to cross-react with other ATPases. This problem was encoun-
tered during early high-throughput screens [26]. Although catalytic
inhibitors can be optimized by chemical modiﬁcation, allosteric inhibi-
tors that disrupt SecA ATPase activity by targeting regions other than
those present in human ATPases offers better prospects [26]. In fact,
most SecA inhibitors identiﬁed (Section 3.3) either compete with ATP
binding or prevent ATP hydrolysis by binding to an allosteric site on SecA.
An alternate approach is to identify molecules that prevent SecA-
ligand interactions, resulting in the inhibition of protein translocation.
This area is currently unexplored and there are no inhibition assays spe-
ciﬁcally designed for this purpose. Two important interactions that
could be targeted are SecA-SecYEG and SecA-preprotein interactions.
The structures of SecA bound to nucleotide, SecYEG [103] a signal pep-
tide and a tripeptide [104,105,119] as well as the increasing knowledge
of the binding sites on SecA for interactionwith these ligands [116,139],
provide the basis for rational inhibitor design. Several pockets at the
SecA surface are proposed as druggable sites in addition to the large
groove 1 and a deep pocket formed by residues of the PBD and the C-
terminal domain of SecA [130]. This is a unique approach as there are
currently no drugs based on this type of interaction.
3.2. SecA inhibition assays
3.2.1. In vitro assays
3.2.1.1. ATPase activity assay. ATPase activity of SecA alone (basal/
intrinsic) or SecA with membrane (membrane ATPase) or SecA with
membrane and preprotein (translocation ATPase), is commonly mea-
sured by colorimetric determination of the released phosphate using
malachite green [140]. The SecA translocation ATPase assay, adapted
to a 96-well format by researchers at Pﬁzer [141], demonstrated the
activity of SecA inhibitor, CJ-21,058 (Section 3.3.2). To simplify the
in vitro ATPase assay for high-throughput inhibitor screening, a SecA
mutant (Trp to Ala, at position 775, E. coli numbering) was designed
with elevated intrinsic ATPase activity that supports normal protein
translocation both in vitro and in vivo [142]. The use of the SecAmutant
increases the sensitivity of the assay compared to the native SecAwhich
has a low basal ATPase activity and in addition, obviates the need for
membrane (inner membrane vesicles or proteoliposomes containing
SecYEG) and unfolded preprotein components in the reaction mixture.
The assay standardized in a 384-well format is robust (average Z′ factor
[69] of 0.89), and led to the identiﬁcation of novel 5-amino-thiazolo
[4,5-d] pyrimidine inhibitors [143] (Section 3.3.2). Another screening
assay utilized a truncated E. coli SecA devoid of the C-terminal regulato-
ry domain—responsible for the low intrinsic ATPase activity—to identify
ﬂuorescein analogs as inhibitors [144]. The latter two screening assays
are designed to identify active site inhibitors.
3.2.1.2. Preprotein translocation assay. SecA-mediated translocation
of unfolded preprotein substrates (e.g. alkaline phosphatase) in vitro
is monitored by SDS-PAGE followed by immunodetection [140].
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which is quantiﬁed by densitometry [144,145]. These assays are low-
throughput and used as secondary assays to conﬁrm SecA inhibition.
3.2.2. In vivo assays (target-based)
3.2.2.1. Whole cell reporter assay. A cell-based assay involving a recombi-
nant E. coli strainwith a SecA-LacZ fusion reporter systemwas developed
by Wyeth-Ayerst Research for screening for SecA inhibitors [146]. The
assay is based on the property of SecA to autogenously regulate its
mRNA translation in response to changes in secretion levels. Under
normal secretion conditions SecA binds to its own mRNA, inhibiting
translation but when secretion is blocked, mRNA is released and transla-
tion is upregulated. One drawback is that the assay appears to preferen-
tially select compounds that affect membrane integrity [146].
3.2.2.2. Reduced expression of SecA. An assay developed at Merck [147]
utilizes an S. aureus strain that generates antisense RNA against secA
thereby rendering the strain hypersensitive to inhibitors of SecA. A
two-plate agar-based differential sensitivity screen—comparing the ef-
fect of compounds on the sensitized strain versus the wild-type con-
trol—conducted on a high-throughput scale led to the identiﬁcation of
the natural product inhibitor, pannomycin [147] (Section 3.3.3).
3.2.2.3. A common screen for Sec-pathway inhibitors. A high throughput
screening assay designed by Cowther et al. [148] utilizes a recombinant
E. coli strain that accumulates β-galactosidase (β-gal) in its cytoplasm if
translocation through SecYEG is blocked. Presumably, toxic compounds
and nonspeciﬁc protein synthesis inhibitors prevent β-gal production
and do not show up as hits. Although, an initial screen of 800 com-
pounds did not yield reproducible hits, the assay is reliable (average Z′
factor of 0.60, manual screen) and suited for 384-well format.
3.3. Overview of SecA inhibitors
The different approaches (in vitro, in vivo and in silico) for ﬁnding
SecA inhibitors have resulted in only a fewmolecules, described below.
3.3.1. Discovery of sodium azide, a research tool for SecA inhibition studies
Sodium azide was the ﬁrst SecA inhibitor reported (in 1990s),
although its antibacterial activitywas known since the late 19th century
[130]. Sodium azide inhibits translocation ATPase activity (but not
intrinsic ATPase activity) of SecA [Table 5, compound 1], probably by
blocking the de-insertion step and trapping SecA in the membrane
[132,149]. Sodium azide also inhibits other ATPases including mito-
chondrial F-ATPase [150] and several enzymes including cytochrome c
oxidase, superoxide dismutase and alcohol dehydrogenase [151] and
is unsuitable as an antibiotic. Nevertheless, the azide inhibitor demon-
strated SecA as an antibacterial target and has served as a positive con-
trol in SecA inhibition assays [141,142,146,148].
The exact mechanism bywhich sodium azideworks as a SecA inhib-
itor is not known. Based on the mechanism of inhibition of the mito-
chondrial F-ATPase by sodium azide, a comparison can be drawn
[130]. The ternary structure of the complex of F1-ATPase with ADP
and azide [150], shows that the azide anion brings the side chains of
two catalytically essential amino acids closer to the nucleotide, creating
a tighter ﬁt with the ADPmolecule and stabilizing the ADP-bound state.
Since SecA and F1-ATPase bind to adenine nucleotides with a very sim-
ilar geometry [105], a comparable mechanism could explain how sodi-
um azide stabilizes the membrane-inserted, ATP-bound state of SecA
[131,132].
3.3.2. Discovery of equisetin (CJ-21,058), thiazolo[4,5-d]pyrimidine and
ﬂuorescein analogs by the in vitro approach
The ﬁrst natural product inhibitor of SecA, CJ-21,058, isolated from
an unidentiﬁed fungus, is an analog of Fusarium toxin equisetin, witha hydrophilic tetramic acid moiety and a hydrophobic bicyclic moiety
[141]. CJ-21,058 (Table 5, compound 2) inhibits translocation ATPase
activity of E. coli SecA (IC50 of 15 μg/ml), as demonstrated in an
in vitro assay developed by Pﬁzer (see Section 3.2.1.1). The inhibitor is
antibacterial against multi-drug resistant S. aureus and Enterococcus
faecalis (MIC 5 μg/ml) while it has no activity against E. coli and Strepto-
coccus pyogenes. The correlation between SecA inhibition and antibacte-
rial activity and the effect of CJ-21,058 on the intrinsic ATPase activity of
SecAwas not reported [141]. Docking of CJ-21,058 into the active site of
E. coli SecA shows that the molecule binds at the ATP binding site, indi-
cating that it probably competes with ATP for binding [144].
We undertook a high-throughput screen of ~27,000 diverse small-
molecules against E. coli SecAmutant with elevated intrinsic ATPase ac-
tivity (Section 3.2.1.1) [142]. This led to identifying several inhibitors
belonging to different chemical classes, including nipecotic acid deriva-
tives and pyrrolopyrimidines with IC50 values ranging from 50 to 150
μM against wild-type E. coli SecA [130,142]. A further screen of a library
of synthesized thiazolo[4,5-d]pyrimidine derivatives, identiﬁed several
ATPase inhibitors of E. coli and S. aureus SecA1 [143]. Kinetic analysis of
the most potent inhibitor (Table 5, compound 3) revealed a mixed-type
inhibition, with an inhibition constant of 60 μM against translocation
ATPase activity of S. aureus SecA1 [130]. The antibacterial activity was
not signiﬁcant (unpublished data).
Fluorescein analogs (hydroxanthenes), Rose Bengal and Erythrosin
B (Table 5, compounds 4 and 5), identiﬁed from an in vitro screen
employing truncated unregulated E. coli SecA (Section 3.2.1.1), proved
effective inhibitors with IC50 of 0.5 and 2 μM, respectively [144].
Rose Bengal is relatively more potent than Erythrosin B, also against
the full-length (regulated) SecA from E. coli and B. subtilis, as seen in
Table 5. Rose Bengal strongly inhibits the preprotein translocation
in vitro with IC50 of about 0.25 μM (the highest potency among the
SecA inhibitors). While the inhibitor lacks antibacterial activity against
the wild-type E. coli, it has equally potent antibacterial activity against
a permeable leaky E. coli mutant (NR698) and wild-type B. subtilis
(IC50 of 3.1 μM). Thus, the ﬂuorescein analogs are more effective on
Gram-positive bacteria for which outer membrane permeability is not
a problem [144]. It is interesting to note that unlike sodium azide,
Rose Bengal and Erythrosin B inhibit all three ATPase activities of SecA
(basal, membrane and translocation), albeit with different efﬁciencies
as observed in Table 5. An in silico modeling study shows that the ﬂuo-
rescein inhibitors bind at the high afﬁnity ATP-binding site on SecA and
that Rose Bengal and the SecA inhibitor, CJ-21,058 occupy the same
position with the same orientations [144]. Huang et al. [144] indicate
that Rose Bengal and Erythrosin B are competitive inhibitors against
ATP and are likely to be general ATPase inhibitors which aremore effec-
tive on the catalytic SecA ATPase.
A recent SAR study indicates that the xanthene ring in Rose Bengal is
essential for activity and that simpliﬁed analogs with half themolecular
weight of Rose Bengal can be as potent as the parent compound [152].3.3.3. Discovery of Pannomycin by the in vivo approach
Pannomycin (a substituted cis-Decalin) is a secondary metabolite
from the fungus,Geomyces pannorum, identiﬁed in a SecA two-plate dif-
ferential sensitivity antisense assay (Section 3.2.2.2) by researchers at
Merck [147]. Pannomycinwas one among over 115,000 natural product
extracts (derived from both actinomycetes and fungi) screened in the
high-throughput antisense assay, which had a primary hit rate of 0.1%.
Pannomycin [Table 5, compound 6] is structurally similar to the SecA in-
hibitor CJ-21,058, which is comprised of decalin linked to a tetramic
acid. Pannomycin has a weak antibacterial activity (in mM range)
against Gram-positive S. aureus Smith strain, E. faecalis and B. subtilis
as shown in Table 5, but not against S. pneumoniae, H. inﬂuenzae, E. coli
and Candida albicans. Parish et al. [147] attribute the higher antibacterial
activity of CJ-21,058 to the presence of tetramic acid and suggest further
optimization of the pannomycin decalin scaffold. However, the SecA
Table 5
Inhibitors of SecA with their in vitro and in vivo activities.
Compound IC50 MIC against micro-organism Ref.
1 Sodium azide (NaN3) 5 mM a ND [193]
2 38.7 μMa 12.9 μM
12.9 μM
S. aureus 01A1105
E. faecalis 03A1069
[141]
3 5-amino-thiazolo[4,5-d]pyrimidine ~200 μM a 135 μM b ND [143]
4 Rose Bengal 0.9 μM a
25 μM b
5 μM c
7 μM d
0.25 μM e
N1 mM
3.1 μM
3.1 μM
E. coliMC4100
E. coli NR698
B. subtilis 168
[144]
5 Erythrosin B 10 μM a
21 μM b
12 μM c
70 μM d
4 μM e
N10 mM
250–500 μM
250–500 μM
E. coliMC4100
E. coli NR698
B. subtilis 168
[144]
6 Pannomycin ND 0.4 mM
1.4 mM
1.4 mM
B. subtilis
S. aureus Smith
E. faecalis
[145]
7 ND 3.2 μM S. aureusMN8 [146]
8 SEW-05929 ~100 μM f ND [151,154]
9 HTS-12302 ~100 μM f ND [151,154]
10
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Table 5 (continued)
Compound IC50 MIC against micro-organism Ref.
20 μM b
2 μM f
N50 μM
N50 μM
E. coliMC4100
E. coli NR698
[154]
11 50 μM b
2 μM f
N50 μM
N50 μM
E. coliMC4100
E. coli NR698
[154]
12 60 μM b N50 μM
20 μM
E. coliMC4100
E. coli NR698
[154]
13 2.5 μM g ND [155]
14 0.25 μM g 759 μM h A. tumefaciens [156]
15 0.92 μM g 586 μM h A. tumefaciens [156]
16 0.48 μM g 609 μM h A. tumefaciens [156]
17 0.64 μM g 333 μM h A. tumefaciens [156]
18 0.44 μM g 639 μM h A. tumefaciens [156]
1776 S. Rao C.V. et al. / Biochimica et Biophysica Acta 1843 (2014) 1762–1783
1777S. Rao C.V. et al. / Biochimica et Biophysica Acta 1843 (2014) 1762–1783inhibitory activity of pannomycin has not been further validated and its
mode of action remains unclear.
The antisense screening assay is highly sensitive which is reﬂected
by the fact that it could identify a weak inhibitor such as pannomycin.
An earlier attempt at high-throughput screening using a SecA-LacZ re-
porter fusion system (Section 3.2.2.1) identiﬁed a fewmolecules that in-
duced SecA expression (which occurs when secretion is blocked) but all
the hits were found to have a deleterious effect on themembrane [146].
The most potent hit is shown in Table 5 (compound 7).3.3.4. Discovery of inhibitors of SecA (of E. coli and Candidatus Liberibacter
asiaticus) by an in silico approach
The availability of the crystal structure of E. coli SecA [98], enabled in
silico screening of compounds against SecA. Structure-based virtual
screening involves docking of compounds (from an entire library or da-
tabase) into the active site or binding pocket and estimating theoretical
binding energies. Based on these, compounds are selected for in vitro
testing [151,153]. Screening of 60,000 compounds from a commercial
collection (MayBridge database, UK) against E. coli SecA holo-form
(PDB ID: 2FSG), identiﬁed 31 hits of which the two best compounds
SEW-05929 and HTS-12302 (IC50 of 100 μM in each case) [151,154]
are shown in Table 5 [compounds 8 and 9]. Further optimization led
to more potent thiouracil derivatives of the parent compound, HTS-
12302 [154]. As seen in Table 5 [compounds 10, 11 and 12], the thioura-
cil derivatives inhibit the intrinsic ATPase activity of the full-length
E. coli with IC50 values in the range of 20 to 60 μM. They are highly
potent against the truncated E. coli devoid of C-terminal regulatory do-
main. However, the compounds do not have signiﬁcant biological activ-
ity against the wild-type E. coli, except compound 12 [Table 5] which
has some antibacterial activity against NR698 [154].
Interestingly, another structure-based virtual screenwas directed to-
wards ﬁnding SecA inhibitors of (Gram-negative bacterium) Candidatus
Liberibacter asiaticus, the causal agent of Huanglongbing disease of citrus
[155]. In this work, a 3D homology model of Ca. L. asiaticus SecA was
built based on the crystal structure of E. coli SecA (PDB ID: 2FSG) [98].
A total of 5,016 small-molecules, ﬁltered based on physicochemical
properties from ChemBridge and Specs chemical databases, were used
for molecular docking into the active ATP-binding site of Ca. L. asiaticus
SecA. Among the 20 hits selected for biological activity studies,
the highest potency (IC50 of 2.5 μM against Ca. L. asiaticus SecA) was ob-
served for compound 13, Table 5 [155]. The antimicrobial activity is not
known.
Wang et al. [156], further optimized the homology model of Ca.
L. asiaticus SecA using three PDB structures (2VDA, 2FSF and 2FSG) as
templates and virtually docked 20000 compounds from the com-
mercially available ZINC database. Twenty compounds were selected
based on their predicted binding to SecA and tested in vitro for their in-
hibitory activity. Five of these molecules (Table 5, compounds 14 to 18)Notes to Table 5:
NR698 is a permeable leaky mutant of E. coli.
ND: not determined.
compound 2, (E)-1-benzyl-3-[(1-{4-[4-(4-{1-[(E)-[(N-benzylcarbamimidoyl)imino]amin
bromophenyl)-2-({[4-({[4-(4-bromophenyl)-5-cyano-6-oxo-1,6-dihydropyrimidin-2-yl]su
compound 11, 2-({[4-({[5-cyano-6-oxo-4-(4-phenylphenyl)-1,6-dihydropyrimidin-2-yl]sulfan
carbonitrile; compound 12, 2-(benzylsulfanyl)-6-oxo-4-(4-phenylphenyl)-1,6-dihydrop
{[(cyclopropylcarbamoyl)methyl]sulfanyl}-1,3-benzothiazol-6-yl)acetamide; compound 14, N
pound 15, 3-amino-6-phenyl-4-(3,4,5-trimethoxyphenyl)thieno[2,3-b]pyridine-2-carbox
carbamoyl]cyclohexyl}benzamide; compound 17, N-(6-methoxy-1,3-benzothiazol-2-yl)-2-[(
12-oxo-10-(thiophen-2-yl)-2,9-diazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7-tetraen-9-ium.
a IC50 against translocation ATPase activity of E. coli SecA.
b IC50 against intrinsic ATPase activity of E. coli SecA.
c IC50 against membrane ATPase activity of E. coli SecA.
d IC50 against intrinsic ATPase activity of B. subtilis SecA.
e IC50 against in vitro translocation of E. coli preproteins.
f IC50 against intrinsic ATPase activity of truncated, unregulated E. coli SecA (EcN68 SecA).
g IC50 against intrinsic ATPase activity of Ca. L. asiaticus SecA.
h The MBC value is shown instead of the MIC value.were found to inhibit the intrinsic ATPase activity of Ca. L. asiaticus SecA
at nanomolar concentrations (IC50, 0.25–0.92 μM). The inhibitors show
antimicrobial activity against Agrobacterium tumefaciens, which is phy-
logenetically related to Ca. L. asiaticus, although at a high concentration
(see Table 5). While there is a potential to optimize thesemolecules to-
wards developing antimicrobial agents against Ca. L. asiaticus, it would
also be interesting to know their spectrum of activity against other bac-
terial pathogens.
Recently, a 3D-Quantitative Structure–Activity Relationship (3D-
QSAR) model was developed using known SecA inhibitors [157]. As
the numbers of SecA inhibitors increase, such models could facilitate
virtual screening and compound optimization.
All three approaches used for SecA inhibitor screening have been
fruitful in ﬁnding effective inhibitors. In the case of SecA, as many effec-
tive inhibitors (in vitro) lack antibacterial activity especially against
Gram-negative bacteria, it is tempting to infer that the in vivo approach
holds greater promise in ﬁnding novel antibacterials.
4. In brief: attempts to target other protein
secretion channels/components
The three enzymes, SPase II, SPase IV and YidC, the twin-arginine
translocation pathway and the Type I to VI secretion systems, are al-
ready being evaluated as novel targets. These components/pathways
are detailed in other articles in this issue, while this section focuses on
their possible use as antibacterial targets.
4.1. Targeting the lipoprotein (or Type II) signal peptidase
SPase II or the lipoprotein signal peptidase (LspA) is responsible for
processing lipoproteins (diacylglycerylmodiﬁed proteins). The recogni-
tion and cleavage site of LspA lies in a region known as the lipobox,
present in the C-region of the signal peptide. The consensus sequence
of the lipobox in B. subtilis and E. coli is L-A/S-A/G-C. Processing by
LspA occurs just before the invariable cysteine residue that is also the
site of diacylglyceryl modiﬁcation [22]. LspA is a potential antibiotic tar-
get because: LspA is an unconventional aspartic acid protease which
lacks the conserved Asp-Thr/Ser-Gly motif present in (eukaryotic and
viral) aspartic proteases [158]. LspA is absent in eukaryotic cells [14], es-
sential for viability in Gram-negative bacteria such as E. coli but not in
Gram-positive bacteria such as B. subtilis [158] or Lactococcus lactis
[159]. However, in pathogens including M. tuberculosis, LspA plays an
important role in processing virulence determinants. An LspA mutant
in (Gram-positive, acid-fast) M. tuberculosis, is severely attenuated in
virulence tuberculosis models [160]. The active site is accessible to ex-
ogenously added potential inhibitors. InB. subtilis LspA, the catalytic res-
idues are placed on the extracytoplasmic side, just below themembrane
surface [158].o]ethyl}phenyl)piperazin-1-yl]phenyl}ethyl)imino]guanidine; compound 10, 4-(4-
lfanyl}methyl)phenyl]methyl}sulfanyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile;
yl}methyl)phenyl]methyl}sulfanyl)-6-oxo-4-(4-phenylphenyl)-1,6-dihydropyrimidine-5-
yrimidine-5-carbonitrile; compound 13, 2-(1H-1,3-benzodiazol-2-ylsulfanyl)-N-(2-
-(5-ethyl-1,3,4-thiadiazol-2-yl)-1-methyl-9H-pyrido[3,4-b]indole-3-carboxamide; com-
ylic acid; compound 16, 4-[(Z)-N,N′-diaminoimidamido]-N-{1-[(4-methoxyphenyl)
5-methyl-1H-1,3-benzodiazol-2-yl)sulfanyl]acetamide; compound 18, (10R)-5-benzoyl-
1778 S. Rao C.V. et al. / Biochimica et Biophysica Acta 1843 (2014) 1762–1783Although LspA has not been characterized in great detail and no
high-throughput assays are reported yet, at least two effective natural
product inhibitors (Table 6, row 1) are known to block its activity.
Globomycin, a cyclic peptide antibiotic [161] and its synthetic deriva-
tives [162] inhibit SPase II in a non-competitive manner and are bacte-
ricidal against enteric Gram-negative bacteria e.g., E. coli. Recently,
Myxovirescin/Megovalicin/M-230B, a macrocyclic metabolite (polyke-
tide) produced by myxobacteria, was shown to target LspA with 2 to
10 fold better whole cell activity (E. coliMG1655, MIC= 4 μg/ml) com-
pared to Globomycin (E. coli MG1655, MIC = 8 μg/ml) [163]. It has
broad-spectrum antibacterial activity and is non-toxic to eukaryotic
cells, including human cells. Synthesis of Globomycin [164] as well as
Myxovirescin A1 [165,166], has paved the way for SAR studies. The
basic questions that remain to be addressed are: could these inhibitors
lead to effective drugs?What is the structure of the active site? Howdif-
ferent is the structure of LspA in Gram-positive and Gram-negative bac-
teria? Why is the enzyme essential in some bacteria, but not in others?
4.2. Targeting the Type IV prepilin peptidase (Type IV signal peptidase)
Type IV signal peptidases—identiﬁed in several Gram-negative bac-
teria and an increasing number of Gram-positive bacteria—play an
essential role in processing the precursors of Type IV pilin (surface
structures often involved in virulence) andprepilin-like proteins (secre-
tory proteins which possess a Type IV signal peptide, but are not pilin
subunits) [167]. The Type IV SPases span the membrane eight times,
have their active site residues close to the membrane boundaries and
cleave their substrates within the cytoplasm, just proximal to themem-
brane surface [22]. The substrate recognition and cleavage site of the
SPase IV differ from that of SPases I and II. SPase IV cleaves between
the residues Gly and Phe in a conserved region located between the N
and H regions of the signal peptide. It is a bifunctional enzyme, also re-
sponsible for N-methylation of the Phe at position +1 relative to the
cleavage site [22].
Type IV SPase is considered an antivirulence target. The enzyme
plays a central role not only in Type IV pilus biogenesis but also in
toxin and other enzyme secretion, natural competence, DNA transfer
and bioﬁlm formation [168]. Marsh and Taylor [169] demonstrated
that mutation of the V. cholerae SPase IV gene attenuates virulence
in vivo. SPase IV does not have eukaryotic counterpart. It is an unusual
aspartic acid protease which differs from the majority of aspartic acid
proteases in that the active site aspartic acids are not found in theTable 6
Efforts in targeting other protein secretion components or pathways for ﬁnding of novel antiba
Sl. no. Component/pathway Screening assay
1. Lipoprotein signal peptidase
(LspA) or the Type II SPase
-NA-
2. Type IV prepilin peptidase
or the Type IV SPase
In vitro preprotein processing assay
3. YidC E. coli strain underexpressing yidC gene
4. Twin-arginine translocation (Tat) Primary screen measures the extracellular ac
phospholipase C (a potent toxin and a Tat-de
secretion product) in P. aeruginosa. Several fo
assays to evaluate Tat-functionality in vivo
5. Type II secretion system The primary bioluminiscent reporter screen u
P. aeruginosa strain responsive to SecA
depletion or inhibition. Secondary assays (β-l
phospholipase C and elastase secretion) ident
Sec/Tat/Type II inhibitors.
6. Type III secretion system Luciferase reporter gene assay in Yersinia pseu
7. Type IV secretion system In vivo assay that measures interaction of Bru
(an inner membrane protein) with itself and
components of the Type IV secretion apparat
an essential and conserved component of the
secretion system.D(T/S)G motif and the pH optimum for in vitro activity is near neutral
as opposed to acidic (pH 2–4) [167]. The active site of the enzyme is ac-
cessible to inhibitors [167].
Resistant to the classical protease inhibitors (including pepstatin, a
general aspartic acid inhibitor), Type IV signal peptidase is inhibited by a
combination of EDAC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride) and glycinamide (known to inhibit non-pepsin-like acid
proteases) [167]. Rationally designed peptides, mimicking the cleavage
site region of its native substrate inhibit the cleavage activity of Type IV
signal peptidase in vitro [170]. Chemical inhibitors of SPase IV, identiﬁed
by in vitro screening include Voltaren (IC50 ~ 110 μM) and γ-secretase
inhibitor VI (IC50 ~ 500 μM) (Table 6, row 2), among others [170].
Search for potent inhibitors, a detailed understanding of the
characteristics of the enzyme, structure, and distribution (pres-
ence/absence in different bacterial species) will help in further
evaluating SPase IV as a target.
4.3. Targeting YidC (Sec-dependent or independent) membrane protein
insertion
In the case of membrane proteins, the hydrophobic transmembrane
segment region in the nascent protein serves as the signal for targeting
and insertion into the membrane. These proteins are routed to the
SecYEG translocase by Signal Recognition Particle (SRP)-mediated co-
translational targeting [171]. Presumably, a lateral gate in the SecYEG
channel allows membrane protein insertion with the help of YidC
which is positioned close to the channel gate [172]. YidC is an integral
membrane protein that assists in the lateral insertion and assembly of
membrane proteins into the lipid bilayer via the Sec-translocase, but
can also independently function as an insertase (see review [173]).
YidC is essential for cell viability [174]. While Gram-negative bacteria
have one YidC, most Gram-positive bacteria have two YidC homologs
(YidC1 andYidC2) [171]. Deletion of both homologswas shown tobe le-
thal in B. subtilis [175]. YidC homologs are also present in mitochondria
(Oxa1 and Oxa2) and chloroplasts (Alb3) but absent in ER and plasma
membrane of eukaryotes [176]. The YidC/Oxa/Alb3members share con-
served hydrophobic regions comprising 5 transmembrane domains,
representing the catalytically active part [171]. Partial functional com-
plementation has been demonstrated between the homologs Oxa 1
and YidC 2 [176] aswell as between Oxa2 and YidC1/YidC [177,178]. Al-
though the YidC/Oxa/Alb3 family has a common ancestry, the homologs
in bacteria and mitochondria have evolved independently [176]. Givencterial targets.
Inhibitor(s) Reference
Globomycin and Myxiviriscin [161–163]
Voltaren and γ-secretase inhibitor VI [170]
Eugenol and Carvacrol [179]
tivity of
pendent
llow-up
N-phenyl maleimide (one of the two potent
inhibitors identiﬁed)
[186]
ses a
actamase,
ify
5,7-dichlorohydroxyquinoline, one among
the 9 inhibitors effective against P. aeruginosa
and Burkholderia pseudomallei
[194]
dotuberculosis Salicylidene acylhydrazides, effective against
Y. pseudotuberculosiswith broad-spectrum
activity against Gram-negative bacteria
(e.g., Chlamydia, Shigella, and Salmonella species)
[190,195]
cella VirB8
other
us. VirB8 is
Type IV
Inhibitor (B8I-2), belongs to salicylidene acylhydrazide
class of molecules, active against Brucella abortus.
[196,197]
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harm to human cells, needs further investigation.
A recent study utilized an antisense RNA-mediated, yidC down-
regulated E. coli strain to identify two antibacterial essential oils (euge-
nol and carvacrol) that possibly targets YidC [179] (Table 6, row 3). The
mode of action of themolecules is not known. Currently, no other inhib-
itors or assays are reported for this target. In addition, knowing the
exact molecular mechanism by which YidC operates or interacts, a sub-
ject of ongoing research [174], will contribute greatly to this line of
work.
4.4. Targeting the twin-arginine translocation pathway
The Tat-pathway, which uniquely transports folded proteins across
the cytoplasmic membrane, operates in many bacteria. The Tat-pathway
gets its name from two highly conserved arginine residues in the signal
peptide region of the protein, recognized by the Tat-apparatus formem-
brane targeting and transport. The Tat-system is comprised of either
three or two essential integral membrane components, TatABC (as in
Gram-negative E. coli) or TatAC (as in Gram-positive Bacillus), respec-
tively [180,181]. The in vitro data suggests that the subsequent steps
in Tat-mediated transport in E. coli are: binding of the signal peptide re-
gion of the preprotein to TatC which forms a complex with TatB, trans-
location of the protein through a channel of varying size formed by TatA
oligomers and release of the mature protein after removal of SP by the
SPase I. The translocated proteins are subsequently released into
the extracellular environment (in Gram-positive bacteria) or into
the periplasm (in Gram-negative bacteria) for further transport across
the outer membrane and, where applicable, outside the cell via
the Type II secretion system [182]. The Tat-pathway is identiﬁed as
an antivirulence target because several bacterial pathogens (e.g.,
M. tuberculosis, L. pneumophila, P. aeruginosa and B. pseudomallei) utilize
the Tat-pathway for transporting extracellular enzymes and other viru-
lence determinants essential for pathogenesis [183]. The Tat-system is
also functional in plants but no homologues are seen in animals. In
P. aeruginosa, a tatCmutant is severely attenuated in a rat pulmonary
infection model [184], while in M. tuberculosis, the Tat-pathway is
seemingly essential for growth, at least under standard laboratory
conditions [185].
Recently, a high-throughput assay developed for screening inhibi-
tors of the Tat-pathway identiﬁed two compounds that directly affect
its function [186] (Table 6, row 4). The current limitation of the Tat-
pathway as a novel target is the lack of detailed structural and functional
data across different bacterial species due to the relatively recent history
of its discovery (in the mid-nineties). Moreover the Tat-pathway is
present in some but not all bacteria, which narrows down its spectrum.
The Tat-pathway is dependent on the Type I SPase for processing
and release of its preproteins from the membrane [187]. Thus targeting
SPase I will also disrupt the Tat-mediated protein secretion.
4.5. Targeting the Type I to VI secretion systems in Gram-negative bacteria
Protein secretion in Gram-negative bacteria is either a one-step or
two-step process. In the latter case, the proteins ﬁrst cross the inner
membrane (via the Sec-pathway or in some cases, the Tat-pathway)
and then cross the outer membrane to reach the external environment.
Gram-negative bacteria possess at least six specialized secretion sys-
tems (Type I to VI), of which Type II and Type V are terminal branches
of the Sec-pathway while the others export proteins directly from the
cytoplasm to the outside milieu or even into the eukaryotic host cells
(see review [188]). These secretion systems are required for transport
of proteins essential for pathogenesis (e.g., toxins, enzymes, anti-host
factors), bioﬁlm formation, and interaction with host or nutrient acqui-
sition, and hence, are good anti-virulence targets [189], but are not es-
sential for viability. Components of the Type II, Type III and Type IV
secretion systems are already pursued as targets and this line of workresulted in high-throughput screening and identiﬁcation of inhibitors
of the secretion systems (Table 6, rows 5 to 7). We refer the interested
reader to [190–192] for detailed reviews on the targeting of secretion
systems for bacterial virulence inhibitors. Itmust be noted that the com-
ponents that make up the Type I to VI secretion apparatus are inserted
into the membrane or exported by the Sec-system [22], and hence,
targeting the Sec-pathway would also render these secretion systems
defunct.
The alternative approach of using antivirulence targets to disarm
bacteria and contain infection also looks promising. However, the chal-
lenges of exploiting them in monotherapy or combination therapy will
only become clear once the inhibitors are developed into drugs.
5. Concluding remarks
The Sec-pathway components, SPases I and SecA are universal, con-
served and essential in bacteria and can be differentially targeted with-
out signiﬁcant harm to humans or animals. They are characterized and
validated targets in non-pathogenic as well as pathogenic bacteria in-
cluding E. coli, S. aureus, P. aeruginosa andM. tuberculosis. Different ap-
proaches have been applied to discover SPase I and SecA inhibitors, for
over two decades. We have witnessed a transition in the approach
from random high-throughput screening using the isolated enzyme to
whole cell antibacterial or target-based whole cell screening. SPase I in-
hibitors, arylomycins (including actinocarbasin) and krisynomycin are
good starting points for optimization towards novel antibacterials.
SPase I, being a single-enzyme target, can evolve resistance by point-
mutation. Preclinical assessment of resistance development is impor-
tant while evaluating new drug leads based on SPase I. SPases I can
also be exploited in combination therapy as demonstrated by synergy
of SPase I inhibitors with β-lactams and an aminoglycoside, gentamicin.
This idea is further supported by the observation that the SPase I
inhibitor, M131, in combination with Imipenem suppresses emergence
of resistance. There are currently no antibacterial candidates targeting
SecA. Although a few effective active site inhibitors have been identiﬁed
using in silico, in vitro and in vivo approaches, allosteric inhibitors with
good antibacterial properties are desirable. Assays speciﬁcally designed
for ﬁnding SecA inhibitors that block its interaction with SecYEG and or
preproteins might be beneﬁcial. Despite several crystal structures of
SecA and continuing efforts, its mode of action is not completely under-
stood. The availability of high-resolution crystal structures especially
that of SecA actively engaged in translocation of preprotein in the
protein conducting channel could ﬁne tune the in silico approach for
screening or optimizing the identiﬁed molecules. Similarly, crystal
structure of the full length SPase I including that from Gram-positive
bacteria will be helpful. The Tat-pathway and the bacterial secretion
systems—Type II, Type III and Type IV—have been pursued as anti-
virulence targets, resulting in a few inhibitors. In comparison with
SPase I or SecA, these targets are not necessarily broad-spectrum and
are not bactericidal. In addition, targeting the SPase I will disrupt the
Tat-pathway and the terminal branches of the Sec-pathway (Type II
and Type V secretion systems), while targeting SecA will either disrupt
or severely affect the additional (Type I to Type VI) secretion systems.
The Sec-pathway components, YidC, SPase II and SPase IV are also
valid targets which need further work. In essence, the Sec-pathway
does offer some good targets for novel antibacterial research.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.02.004.
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